Phase 3 Readout~month

Phase 3 Topline: A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant With Ribociclib Versus L

Indication
Breast Cancer; Metastatic Breast Cancer; Locally Advanced Breast Cancer

Other upcoming events for OLMA

Phase 3 ReadoutPhase 3 Topline: A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment
Patent ExpiryPatent/Exclusivity Expiry: PIQRAY
Patent ExpiryPatent/Exclusivity Expiry: VIJOICE

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant With Ribociclib Versus L — OLMA Phase 3 Readout | BioSniper